Article
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer
2025-12-10
Abstract excerpt
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a dismal prognosis. More than 90% of PDAC tumors harbor KRAS mutations, and several KRAS inhibitors, such as off-state, on-state, mutation-specific, and pan-RAS inhibitors, are being tested in preclinical and clinical settings. However, the response to these inhibitors as single agents is less than optimal, indicating the need to identify novel...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- efa2a8b4-631a-56ed-ad9f-1d13093c8e86
- DOI
- 10.64898/2025.12.06.692635